iOrganBio, an innovator in intelligent cell manufacturing, today announced the appointment of Lee L. Rubin, Ph.D., to its Scientific Advisory Board. Dr. Rubin is a prominent figure in stem cell biology, regenerative medicine, and translational neuroscience, whose research has significantly advanced the understanding of neurodegenerative diseases and contributed to multiple therapeutic candidates.
Dr. Rubin serves as Co-Director and Principal Faculty of the Harvard Stem Cell Institute and is a professor in Harvard’s Department of Stem Cell and Regenerative Biology. His pioneering work includes blood-brain barrier biology, neural stem cell differentiation, disease modeling using patient-derived induced pluripotent stem cells, and the discovery of therapeutic candidates for disorders such as Parkinson's disease, amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA).
His appointment is expected to bolster iOrganBio's capabilities in neurological applications, leveraging the company's CellForge platform. CellForge combines AI prediction, biological sensing, and automated 3D incubation to engineer human cells and organoids with greater precision and consistency. This platform enables scalable production for disease modeling, drug discovery, and cell therapy development. According to the company, Dr. Rubin's extensive academic and entrepreneurial leadership will be key to expanding the platform's reach in neuroscience.
iOrganBio's CellForge platform uses AI and automation to guide cell development and make real-time adjustments aligned with defined biological profiles. At its core is the functional human CellAtlas™, a comprehensive reference built from single-cell and multi-omics data that provides digital blueprints for each cell type. This smart, closed-loop process aims to deliver the accuracy, efficiency, and quality needed to accelerate disease modeling, regenerative medicine, and drug development.
For more details, including downloadable images and bios, view the full announcement here.
